menu
    • menu
    [{"orgOrder":0,"company":"Calyptus Pharmaceuticals","sponsor":"Provepharm Life Solutions","pharmaFlowCategory":"D","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","country":"U.S.A","productType":"Large molecule","year":"2022","type":"Partnership","leadProduct":"Cetrorelix Acetate","moa":"","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Approved","graph3":"Calyptus Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Gynecology\/Obstetrics","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Calyptus Pharmaceuticals \/ Provepharm","highestDevelopmentStatusID":"12","companyTruncated":"Calyptus Pharmaceuticals \/ Provepharm"},{"orgOrder":0,"company":"Akorn Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","country":"U.S.A","productType":"Large molecule","year":"2022","type":"Not Applicable","leadProduct":"Cetrorelix Acetate","moa":"","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Approved","graph3":"Akorn Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Gynecology\/Obstetrics","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Akorn Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Akorn Pharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"Calyptus Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","country":"U.S.A","productType":"Large molecule","year":"2022","type":"Not Applicable","leadProduct":"Cetrorelix Acetate","moa":"","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Approved","graph3":"Calyptus Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Gynecology\/Obstetrics","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Calyptus Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Calyptus Pharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"Akorn Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","country":"U.S.A","productType":"Large molecule","year":"2022","type":"Not Applicable","leadProduct":"Cetrorelix Acetate","moa":"","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Approved","graph3":"Akorn Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Gynecology\/Obstetrics","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Akorn Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Akorn Pharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"Apotex Fermentation Inc.","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","country":"CANADA","productType":"Peptide","year":"2024","type":"Not Applicable","leadProduct":"Cetrorelix Acetate","moa":"","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Approved","graph3":"Apotex Fermentation Inc.","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Gynecology\/Obstetrics","amount2New":0,"dosageForm":"","sponsorNew":"Apotex Fermentation Inc. \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Apotex Fermentation Inc. \/ Not Applicable"},{"orgOrder":0,"company":"Fresenius SE & Co. KGaA","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","country":"GERMANY","productType":"Peptide","year":"2024","type":"Not Applicable","leadProduct":"Cetrorelix Acetate","moa":"","graph1":"Technology","graph2":"Approved","graph3":"Fresenius SE & Co. KGaA","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Technology","amount2New":0.10000000000000001,"dosageForm":"","sponsorNew":"Fresenius SE & Co. KGaA \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Fresenius SE & Co. KGaA \/ Not Applicable"}]

    Find Clinical Drug Pipeline Developments & Deals for Cetrorelix

    Menu

    Cetrorelix

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    FINISHED DOSAGE FORMULATIONS

    DRUG PRODUCT COMPOSITIONS

    DIGITAL CONTENT

    GLOBAL SALES INFORMATION

    MARKET PLACE

    PATENTS & EXCLUSIVITIES

    REF. STANDARDS & IMPURITIES

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Fresenius SE & Co. KGaA

                            Germany arrow
                            Antibody Engineering
                            Not Confirmed

                            Fresenius SE & Co. KGaA

                            Germany arrow
                            Antibody Engineering
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Cetrorelix Acetate

                            Therapeutic Area : Obstetrics/Gynecology (Women’s Health)

                            Study Phase : Approved

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Fresenius Kabi Expands Women's Health with New Reproductive Health Generic

                            Details : Cetrorelix Acetate for Injection is a synthetic decapeptide with GnRH antagonist, indicated for the inhibition of premature LH surges in women undergoing controlled ovarian stimulation.

                            Brand Name : Cetrotide-Generic

                            Molecule Type : Peptide

                            Upfront Cash : Not Applicable

                            August 27, 2024

                            Lead Product(s) : Cetrorelix Acetate

                            Therapeutic Area : Obstetrics/Gynecology (Women’s Health)

                            Highest Development Status : Approved

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Apotex Fermentation Inc.

                            Canada arrow
                            Antibody Engineering
                            Not Confirmed

                            Apotex Fermentation Inc.

                            Canada arrow
                            Antibody Engineering
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Cetrorelix Acetate

                            Therapeutic Area : Obstetrics/Gynecology (Women’s Health)

                            Study Phase : Approved

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Apotex Corp. Launches Generic Fertility Treatment Injectable Cetrorelix® in the US

                            Details : Cetrorelix Acetate for Injection is a synthetic decapeptide with GnRH antagonist, indicated for the inhibition of premature LH surges in women undergoing controlled ovarian stimulation.

                            Brand Name : Cetrotide-Generic

                            Molecule Type : Peptide

                            Upfront Cash : Not Applicable

                            May 14, 2024

                            Lead Product(s) : Cetrorelix Acetate

                            Therapeutic Area : Obstetrics/Gynecology (Women’s Health)

                            Highest Development Status : Approved

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Akorn Pharmaceuticals

                            U.S.A arrow
                            Antibody Engineering
                            Not Confirmed

                            Akorn Pharmaceuticals

                            U.S.A arrow
                            Antibody Engineering
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Cetrorelix Acetate

                            Therapeutic Area : Obstetrics/Gynecology (Women’s Health)

                            Study Phase : Approved

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Akorn Introduces FDA-approved Generic Cetrorelix Acetate for Injection 0.25 mg at ASRM

                            Details : Cetrorelix Acetate is used to prevent premature ovulation during controlled ovarian stimulation. Cetrorelix blocks the effects of a natural hormone, called GnRH. GnRH controls the secretion of another hormone, called LH, which induces ovulation during th...

                            Brand Name : Cetrorelix Acetate-Generic

                            Molecule Type : Large molecule

                            Upfront Cash : Not Applicable

                            October 27, 2022

                            Lead Product(s) : Cetrorelix Acetate

                            Therapeutic Area : Obstetrics/Gynecology (Women’s Health)

                            Highest Development Status : Approved

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            Calyptus Pharmaceuticals

                            U.S.A arrow
                            Antibody Engineering
                            Not Confirmed

                            Calyptus Pharmaceuticals

                            U.S.A arrow
                            Antibody Engineering
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Cetrorelix Acetate

                            Therapeutic Area : Obstetrics/Gynecology (Women’s Health)

                            Study Phase : Approved

                            Sponsor : Provepharm Life Solutions

                            Deal Size : Undisclosed

                            Deal Type : Partnership

                            DEALS_DEV arrow-down

                            Calyptus Pharmaceuticals Announces Partnership with Provepharm to Accelerate Development of an Acute Care Inje...

                            Details : Provepharm acquired global rights of the Cetrorelix acetate from Calyptus and will take on all development activities and ultimately commercial distribution upon approval.

                            Brand Name : Cetrorelix Acetate-Generic

                            Molecule Type : Large molecule

                            Upfront Cash : Undisclosed

                            August 22, 2022

                            Lead Product(s) : Cetrorelix Acetate

                            Therapeutic Area : Obstetrics/Gynecology (Women’s Health)

                            Highest Development Status : Approved

                            Sponsor : Provepharm Life Solutions

                            Deal Size : Undisclosed

                            Deal Type : Partnership

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            Calyptus Pharmaceuticals

                            U.S.A arrow
                            Antibody Engineering
                            Not Confirmed

                            Calyptus Pharmaceuticals

                            U.S.A arrow
                            Antibody Engineering
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Cetrorelix Acetate

                            Therapeutic Area : Obstetrics/Gynecology (Women’s Health)

                            Study Phase : Approved

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Calyptus Pharmaceuticals Announces FDA Approval of Cetrorelix Acetate for Injection, 0.25 mg/vial

                            Details : Cetrorelix Acetate for Injection, 0.25 mg/vial is indicated for the inhibition of premature luteinizing hormone surges in women undergoing controlled ovarian stimulation.

                            Brand Name : Cetrorelix Acetate-Generic

                            Molecule Type : Large molecule

                            Upfront Cash : Not Applicable

                            August 19, 2022

                            Lead Product(s) : Cetrorelix Acetate

                            Therapeutic Area : Obstetrics/Gynecology (Women’s Health)

                            Highest Development Status : Approved

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            06

                            Akorn Pharmaceuticals

                            U.S.A arrow
                            Antibody Engineering
                            Not Confirmed

                            Akorn Pharmaceuticals

                            U.S.A arrow
                            Antibody Engineering
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Cetrorelix Acetate

                            Therapeutic Area : Obstetrics/Gynecology (Women’s Health)

                            Study Phase : Approved

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Akorn Announces FDA-Approved Generic Cetrorelix Acetate for Injection 0.25 mg

                            Details : Cetrorelix Acetate for Injection 0.25 mg is used to prevent premature ovulation during controlled ovarian stimulation, for Injection blocks such undesirable premature ovulation.

                            Brand Name : Cetrorelix Acetate-Generic

                            Molecule Type : Large molecule

                            Upfront Cash : Not Applicable

                            August 16, 2022

                            Lead Product(s) : Cetrorelix Acetate

                            Therapeutic Area : Obstetrics/Gynecology (Women’s Health)

                            Highest Development Status : Approved

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth